Top Page
Profound Medical
(TSX:PRN)
Profound Medical (PRN) vs. iShares MSCI Canada ETF (EWC)
Profound Medical Business Overview & Revenue Model
Profound Medical Earnings Call Summary
Profound Medical Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.77M | 10.68M | 7.20M | 6.68M | 6.87M | 7.30M |
| Gross Profit | 9.88M | 7.04M | 4.38M | 3.02M | 2.95M | 3.47M |
| EBITDA | -40.97M | -32.13M | -27.00M | -34.63M | -28.65M | -19.50M |
| Net Income | -39.64M | -27.82M | -28.57M | -28.67M | -30.70M | -21.62M |
Balance Sheet | ||||||
| Total Assets | 42.30M | 70.23M | 43.91M | 64.42M | 86.78M | 104.60M |
| Cash, Cash Equivalents and Short-Term Investments | 24.83M | 54.91M | 26.21M | 46.52M | 67.15M | 83.91M |
| Total Debt | 277.00K | 5.12M | 7.87M | 8.23M | 1.38M | 1.68M |
| Total Liabilities | 10.16M | 9.81M | 12.73M | 12.42M | 6.16M | 7.25M |
| Stockholders Equity | 32.14M | 60.42M | 31.18M | 52.00M | 80.62M | 97.35M |
Cash Flow | ||||||
| Free Cash Flow | -37.15M | -23.45M | -22.30M | -25.80M | -22.95M | -20.92M |
| Operating Cash Flow | -37.15M | -23.45M | -22.30M | -25.80M | -22.36M | -20.57M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -593.00K | -350.00K |
| Financing Cash Flow | 35.36M | 54.70M | 1.46M | 7.03M | 5.95M | 87.43M |
Profound Medical Technical Analysis
Profound Medical Risk Analysis
Profound Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | C$217.50M | -14.31 | -10.51% | ― | 2.48% | -53.76% | |
55 Neutral | C$427.52M | -6.31 | -127.60% | ― | 72.03% | -1.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$20.96M | -5.04 | ― | ― | 28.59% | 23.46% | |
46 Neutral | C$21.07M | -11.16 | -31.12% | ― | 9.71% | -118.02% | |
46 Neutral | C$31.91M | -1.43 | -181.70% | ― | 209.29% | 35.38% | |
46 Neutral | C$50.13M | -11.14 | -269.41% | ― | 1.46% | 6.91% |
Profound Medical Corporate Events
Profound Medical reported that it exceeded its 2025 goal for TULSA-PRO installations, ending the year with 78 systems deployed versus a target of 75, and disclosed a qualified sales pipeline of 97 additional systems in advanced stages of the sales process. Management highlighted that the expanding installed base is expected to drive higher patient treatment volumes and growth in high-margin recurring revenue, reinforcing the TULSA Procedure’s positioning as a versatile, incision-free option across the prostate disease spectrum and underscoring Profound’s strengthening commercial traction ahead of its upcoming fourth-quarter and full-year 2025 financial results.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$12.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical announced that The Johns Hopkins Hospital has performed its first commercial, non-trial prostate cancer treatment using the company’s TULSA-PRO system, coinciding with the launch of Johns Hopkins Medicine’s new interventional MRI suite designed to turn MRI from a purely diagnostic tool into a real-time therapeutic platform. The milestone places TULSA-PRO within one of the world’s most influential prostate cancer centers, potentially accelerating adoption of the incision-free TULSA Procedure as a mainstream option for prostate cancer and enlarged prostate, and underscores a broader shift toward MRI-guided, minimally invasive therapies that promise faster recovery and fewer side effects compared with traditional surgery or radiation, with positive implications for Profound Medical’s market positioning in advanced prostate care.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. has closed a private placement of 921,428 common shares to Canadian investors at US$7.00 per share, raising approximately US$6.45 million in gross proceeds, with the shares subject to a four-month-plus-one-day hold period under Canadian securities laws. The company plans to deploy the funds to expand sales and marketing, support working capital, and advance research and development and potential strategic transactions, a move that strengthens its balance sheet and provides additional capital to drive commercialization of its MRI-guided therapeutic platforms and broader corporate growth initiatives.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. has upsized its previously announced private placement to raise up to US$6.45 million through the issuance of as many as 921,428 common shares at US$7.00 per share, in order to accommodate demand from a long-term existing investor. The financing, expected to close by December 30, 2025 and subject to a standard four-month-plus-one-day hold period, will provide additional capital to expand sales and marketing, fund working capital and R&D, support potential strategic transactions and general corporate purposes, strengthening the company’s balance sheet as it seeks to scale commercialization of its MRI-guided, incision-free therapeutic platforms in competitive global medtech markets.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. has raised approximately $36 million through a registered direct offering of 5,142,870 common shares priced at $7.00 each, in a deal led by healthcare-focused investors and existing shareholders, with no warrant coverage. The company plans to deploy the net proceeds to expand sales and marketing, bolster working capital, fund research and development, pursue strategic transactions, and support general corporate purposes, and it also intends to complete an additional private placement for certain Canadian investors by December 30, 2025, subject to regulatory approvals, further strengthening its balance sheet and growth capacity.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. has priced a financing of up to $40 million, consisting of a $36 million registered direct offering of 5,142,857 common shares at $7.00 each and a planned $4 million private placement in Canada of up to 571,428 common shares at the same price. The registered direct offering, which carries no warrant coverage and is led by healthcare-dedicated investors alongside existing shareholders, is expected to close around December 22, 2025, while the Canadian private placement, subject to stock exchange and other approvals and a four-month-plus-one-day hold period, is expected to close by December 30, 2025. Profound plans to deploy the net proceeds to expand sales and marketing, bolster working capital, fund research and development, pursue strategic transactions, and support general corporate purposes, reinforcing its capital position as it works to scale commercialization of its prostate disease treatment platform. Konik Capital Partners, a division of T.R. Winston and Company, is acting as exclusive placement agent for the registered direct component.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. announced that Dr. Pejman Ghanouni from Stanford University received the Cum Laude award at the RSNA Annual Meeting for his presentation on the CAPTAIN trial, which compares the TULSA Procedure to robotic radical prostatectomy. The TULSA Procedure has shown significant advantages in recovery time and patient experience, offering a promising alternative to traditional prostate cancer treatments. This achievement highlights the potential of TULSA-PRO as a mainstream treatment option, enhancing Profound Medical’s position in the medical device industry.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical announced the launch of its TULSA-AI Volume Reduction module, designed to optimize the treatment of benign prostatic hyperplasia (BPH), at the RSNA meeting. This new module enhances the TULSA Procedure’s efficiency, allowing multiple prostate cases to be handled in one day, potentially tripling the company’s market reach to 600,000 patients annually. The TULSA Procedure’s benefits, such as reduced risk of sexual dysfunction and quicker recovery times, are expected to drive its adoption among patients and healthcare providers.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical announced a significant milestone as The Hong Center Scottsdale, led by Dr. Y. Mark Hong, completed 200 independent TULSA Procedures for prostate disease. This achievement marks a new standard in MRI-guided prostate therapy, showcasing the potential of incision-free treatments to improve patient outcomes. Dr. Hong’s work highlights the capability of urologists to independently perform the TULSA Procedure, which is expected to transform prostate cancer treatment by offering a less invasive alternative to traditional surgery. The milestone underscores the growing adoption of Profound’s TULSA-PRO system, which provides precise, personalized therapy while preserving patients’ quality of life.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$12.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical reported a significant 87% increase in revenue year-over-year, reaching a record $5.3 million in the third quarter of 2025. The company also saw a notable increase in gross margin to 74.3%, driven by the growing adoption of its TULSA-PRO system. Profound is expanding its market presence with strategic distribution agreements in Canada, Saudi Arabia, Australia, and New Zealand, and has launched a new TULSA-PROgram in partnership with Texas Prostate and Dallas Medical Center. These developments are expected to accelerate the adoption of its prostate treatment technologies and enhance its positioning in the global medical device industry.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. has entered into an exclusive distribution agreement with Getz Healthcare to bring its TULSA-PRO system to Australia and New Zealand. This partnership is expected to enhance precision prostate care in these regions by offering an innovative, incision-free treatment option. The agreement marks a strategic expansion for Profound Medical, allowing them to tap into a significant market where prostate cancer is highly prevalent. The collaboration with Getz Healthcare, a leading distributor in Asia Pacific, aligns with Profound’s strategy to expand its global reach and strengthen its market position in prostate cancer treatment.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. has signed an exclusive distribution agreement with Al Faisaliah Medical Systems to introduce its TULSA-PRO and Sonalleve technologies in Saudi Arabia, the largest healthcare market in the Middle East. This strategic partnership allows Profound to expand its market reach, leveraging FMS’s expertise in the region to deliver its incision-free therapies for tissue ablation. The agreement marks a significant step in Profound’s global expansion strategy, enhancing its industry positioning and offering potential benefits for stakeholders by meeting the specific needs of local clinicians and patients.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. has regained exclusive distribution rights for its TULSA-PRO® system in Canada from Knight Therapeutics Inc. The TULSA-PRO system is used for the ablation of prostate tissue in men with prostate cancer or benign prostatic hyperplasia. This strategic move allows Profound to leverage its North American commercial and clinical teams to expand the TULSA-PRO business in Canada. The company plans to use upcoming trial results to seek coverage from Canadian Provincial Health Insurance authorities, potentially increasing the procedure’s adoption across Canadian hospitals.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical has announced that the Busch Center has successfully completed its 500th TULSA Procedure, showcasing the procedure’s effectiveness in treating various prostate diseases. The TULSA Procedure, an incision-free, MRI-guided treatment, offers a significant advancement in prostate care by providing precise and customizable treatment options, leading to better patient outcomes without the complications associated with traditional methods.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. announced its participation in the Stifel 2025 Healthcare Conference, where management will present a business update. This engagement underscores the company’s ongoing efforts to enhance its industry presence and communicate its innovative medical solutions to stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.